Ono Pharmaceutical Co., Ltd. (OPHLY) Stock Price & Analysis
Ono Pharmaceutical Co., Ltd. (OPHLY) — price $5.11 (-1.16%), as of the Nov 19, 2026 trading session; market cap $7.21B. Expected results Feb 1, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Ono Pharmaceutical Co., Ltd. · OPHLY · Healthcare · Drug Manufacturers - General
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.11 | |
| Change on the day | -1.16% | |
| 52-week range | $4.22–$5.75 | |
| Market capitalisation | $7.21B | — |
| Price / earnings (trailing) | 15.69 | |
| Shares traded on the day | 24.7K | |
| Beta (volatility vs the S&P 500) | 0.14 | |
| Dividends per share (last 12 months) | $0.14 | |
| Dividend yield (last 12 months) | 2.75% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Events are in date order; the spacing is not a duration scale. Estimated dates can change.
Other perspectives
Council score for Ono Pharmaceutical Co. (OPHLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ono Pharmaceutical Co. (OPHLY), and what does it report?
Short answer
Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Healthcare / Drug Manufacturers General Headquarters: 8-2, Kyutaromachi 1-chome, Osaka, OS, 541-8564, JP. It employs 4,206 people and is led by Gyo Sagara. In Q2 FY2027 it reported revenue of ¥116.26B and net income of ¥20.76B. The market values it at $7.21B.
What do the latest results show for Ono Pharmaceutical Co. (OPHLY)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ¥116.26B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $737.15M Oct 29, 2026
- Latest report · revenue estimate
- $725.78M Oct 29, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $737.15M | $725.78M | $0.0934 | $0.0913 |
| Jul 31, 2026 | $729.53M | $685.03M | $0.1076 | $0.0716 |
| May 8, 2026 | $758.15M | $717.88M | $0.0037 | $0.0172 |
| Feb 2, 2026 | $898.67M | $833.28M | $0.1315 | $0.0963 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ¥116.26B | ¥20.76B | ¥14.69 (diluted) |
| Q1 FY2027 | ¥117.69B | ¥24.47B | ¥17.76 (diluted) |
| Q4 FY2026 | ¥120.93B | ¥833M | ¥0.58 (diluted) |
| Q3 FY2026 | ¥142.43B | ¥29.38B | ¥20.85 (diluted) |
What are the financial strengths and risks for Ono Pharmaceutical Co. (OPHLY)?
Short answer · as of
The distress and quality screens read Altman Z 5.52 · Piotroski F 7. Trailing ratios: ROE 8.7% · ROA 6.8% · current ratio 3.32 · earnings yield 6.3% · free-cash-flow yield 10.7%.
What should you watch next at Ono Pharmaceutical Co. (OPHLY)?
Short answer · as of
The next earnings report is expected on Feb 1, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Sep 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Sep 30, 2026
- Reporting holders
- 4 Period end Sep 30, 2026
- Previous quarter · holders
- 6 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| First Command Advisory Services, INC. | 19,951 |
| Rhumbline Advisers | 4,785 |
| Westside Investment Management, INC. | 3,747 |
| Calydon Capital | 2,604 |
Tracked investors
Which of the 16 named investors we follow held OPHLY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported OPHLY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ono Pharmaceutical Co. (OPHLY)?
Common Questions About OPHLY (Healthcare)
These answers are editorial: 1 of these 8 answers is drawn from the OPHLY research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is OPHLY a good stock to buy?
Stock Expert AI does not rate OPHLY buy, sell or hold. Ono Pharmaceutical Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the OPHLY stock price today?
The last price recorded for Ono Pharmaceutical Co., Ltd. (OPHLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the unique considerations for investors in Ono Pharmaceutical Co., Ltd. given its ADR and OTC listing?
Investing in Ono Pharmaceutical Co., Ltd. through its OPHLY ADR on the OTC market presents several unique considerations. As a Level I ADR, it trades on the OTC Other tier, implying less stringent public disclosure requirements compared to major exchanges, which can make due diligence more challenging.
What are the key factors to evaluate for OPHLY?
Evaluate OPHLY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. As global populations age, the incidence of these diseases rises, creating a vast unmet medical need. Not financial advice.
How frequently does OPHLY data refresh on this page?
OPHLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven OPHLY's recent stock price performance?
Ono Pharmaceutical Co., Ltd. (OPHLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across critical therapeutic areas like oncology, diabetes, and neurological disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPHLY overvalued or undervalued right now?
The trailing P/E of Ono Pharmaceutical Co., Ltd. (OPHLY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OPHLY before investing?
Before investing in Ono Pharmaceutical Co., Ltd. (OPHLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 49 figures on this page — 40 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com